Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes
Saurabh Chhabra, Ravi K Narra, Ruizhe Wu, et al.
American Journal of Hematology
|
November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Roland B Walter, Laura C Michaelis, Megan Othus, et al.
Plos One
|
March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review
Yaping Chang, Gordon H Guyatt, Trevor Teich, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood Advances
|
August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Mikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
Mohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2023
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Tamara K Moyo, Ashwin Kishtagari, Matthew T Villaume, et al.
The Lancet. Haematology
|
August 12, 2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
Rory M Shallis, Naval Daver, Jessica K Altman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 10, 2013
Salvage second hematopoietic cell transplantation in myeloma
Laura C Michaelis, Ayman Saad, Xiaobo Zhong, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes
Saurabh Chhabra, Ravi K Narra, Ruizhe Wu, et al.
American Journal of Hematology
|
November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Roland B Walter, Laura C Michaelis, Megan Othus, et al.
Plos One
|
March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review
Yaping Chang, Gordon H Guyatt, Trevor Teich, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood Advances
|
August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Mikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
Mohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2023
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Tamara K Moyo, Ashwin Kishtagari, Matthew T Villaume, et al.
The Lancet. Haematology
|
August 12, 2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
Rory M Shallis, Naval Daver, Jessica K Altman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 10, 2013
Salvage second hematopoietic cell transplantation in myeloma
Laura C Michaelis, Ayman Saad, Xiaobo Zhong, et al.
Page
of 6